Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30007438 | 1.00 | ADORA3 (0.38) | ADORA3ADORA2AADORA2BADORA1CYP3A4 | |
| SCHEMBL30848112 | 0.87 | CYP3A4 (0.34) | ADORA3ADORA2AADORA2BADORA1CYP3A4 | |
| SCHEMBL31668718 | 0.78 | ADRA2A (0.45) | CYP3A4CYP1A2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL8030619 | 0.78 | ADRA2A (0.45) | CYP3A4CYP1A2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL4949270 | 0.78 | CYP3A4 (0.38) | CYP3A4LMNACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL4955235 | 0.77 | MCHR1 (0.36) | CYP3A4LMNACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL25072709 | 0.76 | ALDH1A1 (0.36) | ADORA3ADORA2AADORA2BADORA1CYP3A4 | |
| SCHEMBL20987528 | 0.76 | ALDH1A1 (0.36) | ADORA3ADORA2AADORA2BADORA1CYP3A4 | |
| SCHEMBL2383365 | 0.76 | NOS1 (0.37) | ADORA3ADORA2AADORA2BADORA1LMNA | |
| SCHEMBL19152608 | 0.76 | PRMT5 (0.49) | CYP1A2PRMT5ALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023092175-A1 | NOVEL P2X7 RECEPTOR ANTAGONISTS | THE UNIVERSITY OF SYDNEY (AU) | 2023-06-01 | — | — | WO | claimed |
| EP-0904769-B1 | Keratin fibre dye compositions containing Indazole amine derivatives and dyeing method | OREAL (FR) | 2002-09-25 | — | — | EP | claimed |
| US-6027538-A | OXIDATION DYEING OF KERATINOUS FIBERS CONTAINING AT LEAST ONE COUPLER SELECTED FROM INDAZOLEAMINE DERIVATIVES AND AT LEAST ONE OXIDATION BASE; POWERFUL, NOT VERY SELECTIVE HAIR DYES WHICH ARE CAPABLE OF GENERATING INTENSE COLOR | L'OREAL S.A. (FR) | 2000-02-22 | — | — | US | claimed |
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2026-03-05 | — | — | US | disclosed |
| EP-4647424-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-11-12 | — | — | EP | disclosed |
| EP-4577536-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | Hotspot Therapeutics, Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2024181437-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | 中外製薬株式会社 | 2024-09-06 | — | — | WO | disclosed |
| US-20240287003-A1 | ETHACRYNIC ACID DERIVATIVES AS INHIBITORS OF MPRO PROTEASE AND SARS-COV-2 REPLICATION | UNIVERSITE EUROMEDITERRANEENNE DE FES (MA) | 2024-08-29 | — | — | US | disclosed |
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. | 2024-05-30 | — | — | US | disclosed |
| US-20240150321-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| WO-2024073073-A2 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20120329785-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| WO-2012143143-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012143144-A1 | PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| US-20120129811-A1 | TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-24 | — | — | US | disclosed |
| WO-2012068211-A1 | TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012002577-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | 富士フイルム株式会社 (JP) | 2012-01-05 | — | — | WO | disclosed |
| US-6552021-B2 | Antitumor agent | XENOVA LIMITED (GB) | 2003-04-22 | — | — | US | disclosed |
| US-20010034346-A1 | Pharmaceutical compounds | XENOVA LIMITED, BRITISH BODY CORPORATE (GB) | 2001-10-25 | — | — | US | disclosed |
| US-6027538-A | OXIDATION DYEING OF KERATINOUS FIBERS CONTAINING AT LEAST ONE COUPLER SELECTED FROM INDAZOLEAMINE DERIVATIVES AND AT LEAST ONE OXIDATION BASE; POWERFUL, NOT VERY SELECTIVE HAIR DYES WHICH ARE CAPABLE OF GENERATING INTENSE COLOR | L'OREAL S.A. (FR) | 2000-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150321-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL3 | ADORA3 4655/4885ADORA2A 4537/4885ADORA2B 4854/4885 |
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | MYT1, NTMT1, MYL6 | ADORA3 4153/4885ADORA2A 4649/4885ADORA2B 4390/4885 |
| US-20240287003-A1 | ETHACRYNIC ACID DERIVATIVES AS INHIBITORS OF MPRO PROTEASE AND SARS-COV-2 REPLICATION | ACE2, ACE, TMPRSS2 | ADORA3 3293/4885ADORA2A 2950/4885ADORA2B 2756/4885 |
| US-20120329785-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK3 | ADORA3 4619/4885ADORA2A 4298/4885ADORA2B 4408/4885 |
| US-20010034346-A1 | Pharmaceutical compounds | TOP1, ABCC1, TOP2A | ADORA3 2039/4885ADORA2A 2452/4885ADORA2B 1889/4885 |
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | LRRK2, MAP3K20, MAP3K5 | ADORA3 1970/4885ADORA2A 1538/4885ADORA2B 2373/4885 |
| US-20120129811-A1 | TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | MMP1, MMP3, MMP13 | ADORA3 1107/4885ADORA2A 990/4885ADORA2B 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.